Council for Federal Cannabis
Regulation (CFCR) May Webinar to
Focus on FDA’s Regulatory Impact on
the Cannabis Industry

Next CFCR Event Scheduled for Thursday, May 26, 1:00 - 2:00 p.m. EST

MAY 12, 2022

WASHINGTON, D.C. (May 12, 2022) With consumer safety and public health at its absolute core, the Council for Federal Cannabis Regulation (CFCR) will use its upcoming May webinar to focus on the findings in a recent Food and Drug Administration (FDA) report designed to ensure that regulations presently in place for approved drug products in the marketplace are consistent with regulations applicable to cannabis products for medical use.

 

Scheduled for Thursday, May 26, from 1:00 until 2:00 p.m. Eastern Time over the WebEx Online Digital Platform, the webinar will feature FDA scientists Schuyler Pruyn and Dr. Cassandra Taylor.  The program will be moderated by CFCR’s Executive Director Sarah A. Chase along with Council Advisory Board Member Jack Jacobson, a cannabis, energy and education practices advisor for Thompson Coburn LLC. 

 

The discussion is designed to shed specific light on the nature of Current Good Manufacturing Practices – also known as CGMPs – which regulate information available on public state-run websites and other sources that document the minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging of a drug product to assure it is safe for use. The crux of the conversation will focus on the fact that these same standards should be applicable to medical cannabis products presently in development that may be sold in the United States and will amplify the study and the need for standardized testing protocols and methodologies to ensure consumer safety.

 

“CFCR is committed to working with the FDA to help better inform this industry,” Chase said. “Communication matters and this is an important webinar because of the focus on quality and standards, which will ultimately inform federal regulation. Both CFCR and the FDA are focused on keeping consumer health and safety at the forefront of these conversations."

 

Through their monthly presentations, which take place over the WebEx Video Conference Platform, CFCR has explored various facets of the cannabis industry and the legislative movements.  Last month’s seminar focused on Providing a Safe and Legal Pathway for Medical Cannabis Use in the U.S.  Since its inception, more than 2,500 individuals have witnessed these groundbreaking presentations.

 

Ongoing webinars will take place on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today’s legal cannabis molecules and products. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

Speaker Profiles for the May 26 Webinar:

 

Schuyler Pruyn, M.S.

 

Schuyler Pruyn, M.S. earned her M.S. in pharmaceutical sciences from ACPHS in 2019 and her B.S. in chemistry from the University at Albany in 2017. She joined FDA and the Botanical Review Team (BRT) as a summer fellow in 2018 and returned full-time in July 2019. During her time with BRT, Schuyler worked closely with Dr. Cassandra Taylor, who is as a cannabis subject matter expert (SME). Schuyler trained under Dr. Taylor and assisted with various cannabis initiatives within CDER and across the Agency. In 2021, she spent 3 months working concurrently with BRT and the Intergovernmental Affairs Staff (IGA) in the Office of the Commissioner, and in 2022 she began working in the Office of Executive Programs (OEP) in CDER.

Cassandra Taylor, Ph.D.

 

Cassandra Taylor, Ph.D. is a Chemist at U.S. Food and Drug Administration within the Center for Drug Evaluation and Research (CDER) and is a member of the Botanical Review Team (BRT) residing within the Office of Pharmaceutical Quality (OPQ) and serves as an expert resource on all botanical issues. Dr. Taylor received her B.S. in Chemistry from St. Francis University (2005), and her Ph.D. in Analytical Chemistry from the University of Maryland (2014). Dr. Taylor has evaluated over 100 botanical drug submissions across CDER’s clinical divisions, with a focus on reviewing cannabis submissions. She serves as a cannabis subject matter expert (SME) for CDER and across FDA, concentrating on the botanical and quality aspects of cannabis. Dr. Taylor is the technical lead on the draft FDA guidance for industry titled “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.” She leads and coordinates the internal CDER Cannabis working group and leads many cannabis initiatives within CDER and FDA. Dr. Taylor is an active SME in the FDA cross-agency cannabis working group, Cannabis Products Committee (CPC). She collaborates with colleagues across FDA to help close substantial.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Pruyn_headshot.jpeg
CTaylor_USFDA_CFCR_Picture1.jpg

Sarah A. Chase, Executive Director of the Council for Federal Cannabis Regulation (CFCR) to Appear on 4/20 Virtual Common Sense Cannabis Legislation for Veterans Program

Hosted by the Iraq and Afghanistan Veterans of America, the Alternative Therapies: Cannabis Panel will Stream on Facebook Live This Wednesday, April 20, 4:00 – 5:00 p.m. EST

APRIL 18, 2022

WASHINGTON, D.C. (April 18, 2022) Sarah A. Chase, Executive Director of Council for Federal Cannabis Regulation (CFCR), will participate in an hour-long, virtual program entitled Alternative Therapies: Cannabis Panel, hosted by IAVA – The Iraq and Afghanistan Veterans of America organization, this Wednesday, April 20, starting at 4:00 p.m. EST. The program will stream on Facebook Live.


Headquartered in New York City with an advocacy arm in Washington, D.C. IAVA is solely and exclusively focused on connecting, uniting and empowering military veterans from the post-9/11 era, the predominance of whom served and fought in the Middle East conflicts over the past two decades.


Among the dozens of other major issues on which the organization focuses, high among them is the matter of access to legal, medical cannabis products, to which thousands of veterans have turned as an alternative to opioids and other treatments for the lingering effects of military service, ranging from insomnia and anxiety to treatment of injuries, wounds and PTSD.


“Nearly ninety percent of IAVA members have expressed just how important alternative therapies, like cannabis, have been in treating health conditions sustained during their service,” said Victor Bohm, US Air Force veteran and IAVA’s Senior Director of Digital
Engagement. “Events like this are critical because they allow us to share pertinent information about the alternative therapies available to veterans and help explain what leaders like IAVA, the Balanced Veterans Network, and the Council on Federal Cannabis Regulation are doing to help increase access for our community.”


According to both Bohm and others fighting this battle, the need for both expanded public awareness and actual, impactful legislation was never more vital than it is today.

“In our community, we have thousands of veterans utilizing cannabis as an alternative to pharmaceuticals,” said Ron Millward, founder and president of the Balanced Veterans Network, a 501(c)(3) organization created to provide a safe space for the education, advocacy, and empowerment of alternative therapies for veterans. “We have witnessed countless people
take their health and wellness into their own hands and advocate for a better, more balanced way of living. Veterans deserve options and should not be penalized for how they choose to heal post-service.”

Bohm and Millward will join CFCR’s Chase for a frank discussion about the potential future of federal legislation dedicated to this cause.

 

“Access to safe and legal cannabis is critical for many veterans who return from service with physical or mental wounds,” Chase said. “We have the responsibility to work with the VA, veterans groups, patient advocacy groups, and the federal government to ensure that safe and legal products are available to help them, either as medicine or as therapy.


“Our veterans have done their duty and it’s time the government does right by them. Now is the time for our government to make cannabis safe and legal for our veterans by decriminalizing and destigmatizing at the highest federal level.”

To access the program on Wednesday, April 20 at 4:00 p.m., please click here.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is a 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically, federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses that support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For
additional information please visit www.uscfcr.org and follow us on social media @USCFCR.

ABOUT IAVA
IAVA is the voice for the post-9/11 veteran generation. With over 425,000 veterans and allies nationwide, IAVA is the leader in non-partisan veteran advocacy and public awareness. We drive historic impacts for veterans and IAVA's programs are second to none. Any veteran or family member in need can reach out to IAVA’s Quick Reaction Force at quickreactionforce.org
or 855-91RAPID (855-917-2743) to be connected promptly with a veteran care manager who will assist. IAVA’s The Vote Hub is a free tool to register to vote and find polling information. IAVA's membership is always growing. Join the movement at iava.org/membership.

ABOUT BALANCED VETERANS
The Balanced Veterans Network (BVN) provides education, advocacy, and empowerment of alternative therapies for veterans and their families. BVN is a community that shares knowledge and camaraderie to combat the suicide epidemic, addiction, homelessness, and loss of purpose after leaving the military service. Finding balance in life is a mental, physical, and spiritual
journey. Learn more about Balanced Veterans Network at www.balancedveterans.com or on social media @balancedveterans.

Council for Federal Cannabis Regulation (CFCR) April Webinar to Focus on Providing a Safe and Legal Pathway for Medical Cannabis Use in the U.S.

Next CFCR Event Scheduled for Thursday, April 28, 1:00 - 2:00 p.m. EST

APRIL 12, 2022

WASHINGTON, D.C. (April 12, 2022) According to the National Institutes of Health, despite the increasing prevalence and acceptance of medical cannabis use among the general public, the evidence required by physicians to use cannabis as a treatment has been found to be generally lacking.

 

“Research on the health effects of cannabis and cannabinoids has been limited worldwide, leaving patients, health care professionals, and policymakers without the evidence they need to make sound decisions regarding the use of cannabis and cannabinoids,” is the Institute’s official position, released through a formal statement.

 

On Thursday, April 28, as part of their ongoing monthly webinar series the Council for Federal Cannabis Regulation (CFCR) will take an in-depth look at the current legislation in Congress and the various pathways forward for safe and legal access.  The Council has gathered a dynamic collection of leading physicians and policymakers to discuss the future of medical cannabis use in the United States. The conversation will center around the pros and cons of medical use cannabis with a focus on what the latest research tells us about the future of cannabis and our ability to gain new insights from expanding research. 

 

The webinar will take place, online, from 1:00 until 2:00 p.m. EST.

 

The program will be moderated by CFCR’s Executive Director Sarah A. Chase along with Council Advisory Board Member Jack Jacobson, a cannabis, energy and education practices advisor for Thompson Coburn LLC.  The panel will consist of Rachel Patterson, Senior Director for Federal Relations and Policy of the Epilepsy Foundation; Dr. Jacqueline French, professor of Neurology at NYU the Grossman School of Medicine and Founder/Director of the Epilepsy Study Consortium; Dr. Peter Grinspoon, Primary Care physician at Massachusetts General Hospital; Amanda Kain, Deputy Chief of Staff of the Cannabis Caucus, co-chaired by Rep. David Joyce (R-OH)Co-Chair of the Cannabis Caucus and Reginald Babin; Chief Counsel to Senate Majority Leader Chuck Schumer (D-NY).

 

Through their monthly presentations, which takes place over the ON24 Video Conference Platform, CFCR has explored various facets of the cannabis industry and the legislative movements.  Last month’s seminar – which focused on Understanding Real World Evidence on the Effectiveness of Cannabinoid Products -- drew nearly 100 attendees. Since its inception, more than 2,000 individuals have witnessed these groundbreaking presentations.

Ongoing webinars will take place on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today’s legal cannabis molecules and products. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

 

Speaker Profiles for the April 28 Webinar:

 

Dr. Rachel Patterson

 

Dr. Patterson is Senior Director of Federal Relations & Policy at the Epilepsy Foundation, where she focuses on health care access and disability rights, including safe and legal access to cannabis for people with epilepsy. She has previously served at Health Management Associates, the Christopher and Dana Reeve Foundation, and the Association of University Centers on Disabilities.  Rachel has an MPA from the Maxwell School of Citizenship and Public Affairs at Syracuse University and a BA in Politics from Whitman College in Walla Walla, Washington

 

Upon return to the US, Tim was responsible for the U.S. Region, Commercial Operations.  Tim holds a BA degree in Chemistry and a Master’s Degree in Organizational Leadership.

Dr. Jacqueline French


Dr. French is a professor of Neurology in the Comprehensive Epilepsy Center at NYU Grossman School of Medicine and Founder/Director of the Epilepsy Study Consortium, an academic group that has performed a number of early phase clinical trials in epilepsy and has developed new methodologies for epilepsy trials. Dr. French trained in Neurology at Mount Sinai Hospital in New York, and did her fellowship training in EEG and epilepsy at Mount Sinai hospital and Yale University. Dr French has focused her research efforts on development of new therapeutics for epilepsy, and new methodologies for clinical trials.  She has authored over 300 articles and chapters, is the editor of three books, and lectures internationally on clinical trials and use of antiepileptic drugs.

Dr. Peter Grinspoon

Peter Grinspoon, M.D. is a primary care physician and cannabis specialist at Massachusetts General Hospital, an Instructor at Harvard Medical School and a certified Health and Wellness Coach. He is a Contributing Editor to Harvard Health Publications as well as a TEDx Speaker. He is the author of the memoir ‘Free Refills: A Doctor Confronts His Addiction’. He is a board member of the advocacy group Doctors for Cannabis Regulation. He is a former Associate Director of the Massachusetts Physician Health Service helping physicians with addiction and mental health issues. He advises several companies. 

 

Amanda Kain

 

Amanda Kain serves as the Deputy Chief of Staff and Policy Director for Congressman Dave Joyce (OH-14) where she oversees the Congressman’s portfolio as the lead congressional Republican on cannabis reform. Known for being not only one of the most bipartisan members of congress and a Cardinal leader of the House Appropria-tions Committee, Congressman Joyce secured and enacted into law the only federal programming to allow for the cost of state and local cannabis expungements. Amanda Kain is a native of Northeast Ohio , a graduate of Dickinson College and member of the Congressman’s team for over four years.

Reginald Babin

Reginald Babin serves as Chief Counsel to U.S. Senate Majority Leader Chuck Schumer. Before joining the Office of Leader Schumer in March 2017, Reginald spent three years in the Office of Rep. Cedric L. Richmond (D-LA), serving as Legislative Director and Counsel. Prior to joining Rep. Richmond’s Office, Reginald served as Associate Counsel to the U.S. Senate Homeland Security and Government Affairs Committee, Subcommittee on Federal Contracting and Oversight. Reginald received a B.A. in political science from Louisiana State University in 2010 and a J.D. from The George Washington University School of Law in 2013.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

image002 (6).jpg
sidebar.jackie-french.png
1592059732057.jpg
image001 (6).jpg
image003 (6).jpg

Council for Federal Cannabis Regulation (CFCR)Executive Director Sarah A. Chase to Deliver Keynote Address to Graduates of the University of Maryland School of Pharmacy’s MS in Medical Cannabis Science and Therapeutics Program

Graduation Ceremony Set for Wednesday, May 18, 5 p.m., Universities at Shady Grove

MARCH 22, 2022

WASHINGTON, D.C. (March 22, 2022) Sarah A. Chase, Executive Director of the Council for Federal Cannabis Regulation (CFCR), has been selected as the keynote speaker for the University of Maryland School of Pharmacy’s Masters of Science in Medical Cannabis Science and Therapeutics (MCST) Class of 2022 Graduation Ceremony on Wednesday, May 18, 5 p.m. at the Universities of Shady Grove (USG) in Rockville, Md.

 

The focal point of Chase’s comments will underscore the burgeoning opportunities for “qualified graduates to advance the forward movement of this growing industry – both responsibly and for the betterment of society,” Chase says. A two-year graduate program based at USG, the School of Pharmacy’s program blends online instruction with face-to-face experiences to prepare graduates to respond to the increasing demand for medical cannabis with an understanding of the basic science and clinical uses of the plant. Launched in 2019, it is the first master of science degree program of its kind in the nation.

 

Chase will speak to the program’s 215 graduates, a diverse mix of health care professionals, researchers, entrepreneurs, cannabis industry experts, and advocates, all of whom share CFCR’s values and concerns about ensuring public health, safety, and good science.

 

“The inaugural class of 2021 celebrated their graduation virtually, so this is the first time this program has staged their graduation ceremony in person since the inception of the program,” Chase said. Furthermore, the Council’s executive director will find herself in good company, as Dr. Anthony Fauci, the Chief Medical Advisor to the President of United States, will serve as the keynote speaker for the University of Maryland, Baltimore the next day.

 

In her role as CFCR’s executive director, Chase spearheads the agency’s overall mission to assist and encourage the government – and federal regulatory agencies in particular – to rethink, develop, and implement evidence-based common sense cannabis regulations. “Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of the consumers, professionals, organizations, and businesses who support and serve them,” she said.

 

"We are thrilled to welcome Sarah Chase as our keynote speaker for the 2022 MCST graduation ceremony,” said Chad Johnson, PhD, co-director of the School of Pharmacy’s MS in MCST program and faculty in the department of pharmaceutical sciences. “CFCR’s mission to partner with universities, industry, and research organizations in advancing the scientific understanding of cannabis aligns with our program’s goal to provide our students with an understanding of the basic science and clinical uses of the cannabis plant. Our graduating students will benefit from her words of wisdom and encouragement." 

 

For Chase, the honor of delivering the keynote to such a vital and trailblazing educational audience serves to profoundly substantiate the vision and mission of CFCR, key among which is to further the Council’s key objective to support both scientific research and political legislation. “I’m deeply honored for the opportunity to enrich this community and to speak enthusiastically with the dedicated students graduating from this program,” she said. “These graduates are both the foundation and the future of our industry.”

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Council for Federal Cannabis Regulation (CFCR)March Webinar to Focus on Effectiveness of Cannabinoid Integration into Commercial Products

Next CFCR Event Scheduled for Thursday, march 31, 1:00 - 2:00 p.m. EST

MARCH 8, 2022

WASHINGTON, D.C. (March 8, 2022) The Council for Federal Cannabis Regulation (CFCR) announced today the sixth episode of their monthly webinar series entitled Understanding Real World Evidence on the Effectiveness of Cannabinoid Products.  Scheduled to take place Thursday, March 31, from 1:00 until 2:00 p.m. EST, this program will dive into the results of the recent Radicle ACES (Advancing CBD Education & Science) study and highlight how the real world evidence (RWE) outcomes from the study are helping to better inform consumer perspectives on the effectiveness of cannabinoid-based products. 

 

The program will be moderated by CFCR’s Executive Director Sarah A. Chase along with Council Advisory Board Member Jack Jacobson, a cannabis, energy and education practices advisor for Thompson Coburn LLC.  The panel will consist of Pelin Thorogood and Dr. Jeffrey Chen, the two co-founders of Radicle Science, a transformative health tech company that offers a scalable path toward predicting and validating the effects of health and wellness products for ailments or the enhancement of human function; and Tim Orr, Senior VP of R&D and President of Charlotte’s Web Labs, a company that produced the now-legendary treatment regimen for six-year-old Charlotte Figi that helped to ultimately affect a seismic shift in public opinion toward the use of medicinal cannabis.

 

In a uniquely “democratized” approach to academic research, the Radicle ACES study is the first multi-brand, Institutional Review Board (IRB) approved study on CBD effectiveness across well-being, quality of life, pain, sleep disturbance, and anxiety. The results to be discussed on this webinar shall offer insights on the findings of this first-of-its-kind randomized controlled trial (RCT) that collected health outcome data on 13 participating CBD brands across nearly 3,000 participants throughout the U.S. over a period of four weeks.

 

The event will take place over the ON24 Video Conference Platform, Thursday, March 31, from 1:00 until 2:00 p.m. EST.

 

Through their monthly presentations, CFCR has explored various facets of the cannabis industry – including the regulatory impacts of a groundbreaking CBD study, as well as Federal and state cannabis policies.  Last month’s focus on the Endocannabinoid System and its implications for research and regulation drew more than 300 attendees, pushing their total participation in these programs well past the thousand-person mark. 

 

Ongoing webinars will take place on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today’s legal cannabis molecules and products. These virtual sessions can be viewed through the On24 platform. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

Speaker profiles for March 31, 2022, webinar:

 

Tim Orr, SVP R&D and President Charlotte’s Web Labs

 

Tim Orr is a global healthcare leader with over 30 years healthcare industry experience including general management, strategic and product marketing, U.S. and International sales/marketing/services management, global product development, and global product launch execution. Prior to joining Charlotte’s Web, Tim spent more than 25 years at Johnson & Johnson Company with the $2B Laboratory Sciences Group where he held leadership positions spanning all aspects of commercial operations.

 

Prior to Johnson & Johnson Tim worked for Amersham International, a Life Sciences Company, and Abbott Laboratories. Tim has spent one third of his career living and working in overseas locations including; London England, where was the General Manager responsible for Clinical Labs product development, Tokyo Japan as the Regional Director, and Singapore as General Manager ASPAC region.

 

Upon return to the US, Tim was responsible for the U.S. Region, Commercial Operations.  Tim holds a BA degree in Chemistry and a Master’s Degree in Organizational Leadership.

Pelin Thorogood, Co-Founder, Executive Chairwoman, Radicle Science


Tech CEO, Impact Entrepreneur and Trailblazer -- Pelin Thorogood is an analytics industry executive-turned startup founder who has made a career out of being at the forefront of emerging business trends and disruptive technologies.

 

With an unwavering focus on data and analytics, Pelin served as CEO and Director of Anametrix, a venture-backed multichannel data collection, visualization, and predictive analytics platform which received broad industry recognition, including for best business intelligence (BI) and Big Data solution (acquired by Ensighten 2014). Prior to Anametrix, she was CMO of WebSideStory, the pioneer in web analytics (IPO 2004, acquired by Omniture/Adobe 2008).

 

Pelin is the Co-Founder and President of Wholistic Research, and Education Foundation, one of the very first non-profits (501c3) focused on funding cutting-edge cannabinoid research and education to improve public health and safety. With a deep commitment to education and community, Pelin also serves as a Trustee and Treasurer of the UC San Diego Foundation and is on the Executive Board of the UC San Diego Basement, a campus-wide incubator for innovation and entrepreneurship. Pelin earned her B.S., M.Eng. and MBA degrees on merit scholarships, all from Cornell, where she still serves as an Industry Scholar for Cornell Institute of Healthy Futures.

Dr. Jeff Chen, Co-Founder & CEO, Radicle Science


Scientist, impact entrepreneur and chief storyteller for Radicle Science, Dr. Jeff Chen was the founder and a past Executive Director of the UCLA Cannabis Research Initiative (one of the world's first), which he grew to encompass more than 40 members of the institutional faculty, conducting research, education, and policy projects.

 

Jeff has experience as Founder, Managing Partner, Investor, Board Member, and Advisor to companies, not-for-profits, and venture firms in life science, sustainability, tech, and media. Featured in such media outlets as Rolling Stone, the Wall Street Journal, VICE, CNN, NPR, Entrepreneur, Business Insider, Politico and others, Jeff is part of the Medical Team at Healthline Media (86M visitors/month). He’s a David Geffen Fellow, U.S. patent holder, Industry Mentor for the U.S. National Institutes of Health Innovation CORPs, and Chief Science Officer of the Wholistic Research and Education Foundation.

 

Jeff earned his MD and MBA concurrently at UCLA on a full merit scholarship, following a B.S. at Cornell.

 

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

download.jpg
Pelin-Thorogood_edited.jpg
JeffChenPicture1.jpg

Council for Federal Cannabis Regulation (CFCR) February Webinar to Focus on Implications for Research and Regulatory Science

Next CFCR Event Scheduled for Thursday, February 24, 1:00 - 2:00 p.m. EST

FEBRUARY 10, 2022

WASHINGTON, D.C. (February 10, 2022) The Council for Federal Cannabis Regulation (CFCR) announced today the fifth installment of their monthly web series. February’s virtual conversation, entitled The Endocannabinoid System: Implications for Research and Regulatory Science, is designed to educate the public, policy makers, and industry about the research and regulatory science surrounding the endocannabinoid system – including the cannabis-derived products that impact the human body and their current and potential future use when infused into everything from pharmaceuticals to cosmetics.

 

Moderated by CFCR’s Executive Director Sarah A. Chase along with Council Advisory Board Member Jack Jacobson, a cannabis, energy and education practices advisor for Thompson Coburn LLC, the panel will consist of FDA Scientists Cassandra Taylor, Ph.D. and Dan Mellon, Ph.D., Dr. Vicki Seyfert-Margolis, Chairwoman of CFCR’s Science and Regulatory Affairs Committee, molecular geneticist Dr. Reggie Gaudino, also a member of that same committee and Mara Gordon, co-founder of Aunt Zelda’s, a pioneering, data-driven developer of cannabis-based plant medicines.

Offering in-depth subject knowledge of the still under-studied and often misunderstood endocannabinoid system, each of the three panelists will bring a uniquely varied area of expertise from molecular genetics, immunology, and patient advocacy. This webinar will help to unpack some of the complexity surrounding the long-term considerations for researchers and regulators. 

 

The event will take place over WebEx Video Conference, Thursday, February 24, from 1:00 until 2:00 p.m. EST.

 

With roughly 125 monthly listeners already since debuting last September, CFCR has explored various facets of the cannabis industry in their monthly webinar series – including the regulatory impacts of a groundbreaking CBD study, as well as Federal and state cannabis policies.

 

Ongoing webinars will take place on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today’s legal cannabis molecules and products. These virtual sessions can be viewed on WebEx. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

Speaker profiles for February 24, 2022, webinar:

 

Cassandra Taylor, Ph.D., Chemist, US Food and Drug Administration

 

Cassandra Taylor, Ph.D. is a Chemist at U.S. Food and Drug Administration within the Center for Drug Evaluation and Research (CDER) and is a member of the Botanical Review Team (BRT) which resides within the Office of Pharmaceutical Quality (OPQ). BRT collectively serves as an expert resource for CDER on all botanical issues. Dr. Taylor received her B.S. in Chemistry with a minor in Forensics from St. Francis University in Loretto, PA (2005), and her Ph.D. in Analytical Chemistry from the University of Maryland in College Park, MD (2014). 

 

Dr. Taylor joined FDA in December 2014 as a primary BRT reviewer and has evaluated over 100 botanical drug submissions from all CDER’s clinical divisions, with a focus on reviewing cannabis submissions. She serves as a cannabis subject matter expert (SME) for OPQ, CDER and across FDA, primarily concentrating on the botanical and quality aspects of cannabis.

Dan Mellon, Ph.D., Director of Pharmacology/Toxicology, U.S. Food and Drug Administration


Sr. Mellon holds the lengthy title of Deputy Director for the Division of Pharmacology/Toxicology for Neuroscience and Pharmacology Toxicology Supervisor supporting the Division of Anesthesiology, Addiction Medicine, and Pain Medicine Office of New Drugs Center for Drug Evaluation and Research.

 

He obtained his BS in biology from Allegheny College in Meadville, PA, his PhD in Pharmacology from Georgetown University, and completed post-doctoral research at the National Cancer Institute prior to joining the FDA.  He began his career at FDA as a Pharmacology Toxicology Reviewer in the Division of Anesthetics, Critical Care, and Addiction Drug Products in the fall of 2001. In August of 2003, Dr. Mellon was promoted to the Pharmacology Toxicology Supervisor.

 

He is currently the Deputy Director for the Division of Pharmacology Toxicology for Neuroscience.

Vicki Seyfert-Margolis, Chairwoman, CFCR Science & Regulatory Affairs Committee


Vicki Seyfert-Margolis, Ph.D. founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family-based co-management of health. Previously, Vicki was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science.

 

Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Vicki oversaw the development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation.

 

Dr. Reggie Gaudino, Science & Regulatory Affairs Committee


Dr. Reggie Gaudino is a molecular geneticist focused on biochemical networks in plant phytochemistry. After finishing his PhD in molecular genetics at the University of Buffalo in New York, investigating the biochemistry of transcription initiation and termination in E.coli, he started his postdoc at Washington University in St. Louis investigating control of gene expression, including showing specific Cytokinin responsive RNA Polymerase I transcription initiation in isolated A.thaliana nuclei.  

 

During a particularly austere funding period in the mid-nineties Dr. Gaudino, pursued a legal path to incorporate biotechnology with intellectual property - having been involved in many incarnations of recombinant DNA technologies, DNA sequencing, RNA analysis, in vitro promoter analysis and codon optimization for reporter gene systems in organisms ranging from bacteria to plants. Dr. Gaudino spent the next 22 years working as a patent scientist or Patent Agent with a number of national law firms, and was the Lead Scientist on the Litigation support team in an early, highly publicized, plant biotechnology patent litigation.  

 

Dr. Gaudino and his team have contributed to the general body of knowledge for this under-studied model organism, through several peer-reviewed scientific publications. Dr. Gaudino’s role as a scientific leader at Front Range Bioscience includes programs expressing Cannabis genes in yeast and insect cell lines, performing in vitro gene expression with purified recombinant proteins to study gene function of closely related but functionally different genes, chemotype and phenotype analysis of the germplasm in many disparate breeding programs and developing IP support and protection for any plant or processes that are created through the various programs for which he has oversight.

Mara Gordon, Co-Founder, Aunt Zelda’s


Mara Gordon is a cannabis advocate, entrepreneur, and researcher. She has harnessed her background as a process engineer to create therapeutic dosing regimens for thousands of patients around the world, drastically improving their health, quality of life and longevity. Mara openly shares her knowledge about the therapeutic benefits of the cannabis plant – whether consulting with medical teams, through TEDx Talks or calling out hyperbole in the industry about which she cares so deeply.

 

Mara rose to prominence through the company she co-founded, Aunt Zelda’s. Back in 2011, Aunt Zelda’s operated as a collective, bringing bespoke cannabis formulations to patients. As additional regulations were introduced in California, Mara standardized her most popular therapeutic oil blends, making them commercially available to patients through the respected Aunt Zelda’s brand.

 

As interest in cannabis spreads, Mara continues to be an outspoken leader in the medical cannabis space. She has appeared on stage in front of audiences nationally and internationally and was featured in the films The Medicine in Marijuana, Mary Janes: Women of Weed, and the award-winning documentary Weed the People.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

CTaylor_USFDA_CFCR_Picture1.jpg
Vicki_Headshot-300x300_edited.jpg
DMellon_USFDA_CFCR_Picture1.jpg
5de92a7dbbf4da1e2a27a6d5_team-reggie.jpg
Nataliya-Arditi-3-1200x1800.jpg

Michael J. Fox Foundation Policy SVP
to Join Board of Directors of the Council for Federal Cannabis Regulation (CFCR)

JANUARY 13, 2022

WASHINGTON, D.C. (Thursday, January 13, 2022)  –  Today, the Council for Federal Cannabis Regulation (CFCR) announces Ted Thompson, JD, senior vice president for public policy at The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will join CFCR leadership as a member of their Board of Directors.

 

Thompson brings more than 25 years’ experience in public policy, government relations and nonprofit management to CFCR’s overall mission to create a regulatory framework around the use of cannabis and MJFF’s goal of removing the barriers to research on cannabis as a possible therapeutic option.

 

Increasing Access to Cannabis for Parkinson’s Research and Care

Cannabis — including marijuana and CBD products — has shown early potential to help treat and manage Parkinson’s disease (PD). But restrictions, including marijuana’s status as a Schedule I controlled substance, have blocked needed research that could advance it as a therapeutic approach to Parkinson’s.

 

Today, an estimated 6 million people worldwide live with Parkinson’s, a number that by some estimates could double by 2040. Funding and enabling rigorous research into every potentially promising therapy for Parkinson’s is fundamental to The Michael J. Fox Foundation’s mission to accelerate better treatments and a cure for the benefit of these millions of individuals.

 

“People and families living with Parkinson’s disease have the right to demand public and private support for research into every potential treatment, including medical cannabis, that could safely and effectively help manage the disabling motor and non-motor symptoms of PD,” Thompson said. “As a member of the CFCR Board I’ll work to help create momentum on legislative and other regulatory fronts for improved access to cannabis in Parkinson’s research and care.”

 

A Background in Advocating for People and Families Living with Disease

Thompson served as president and CEO of the Parkinson’s Action Network (PAN) from 2014 to 2016, at that time the unified voice of Parkinson’s advocacy in Washington, D.C. In 2016 Thompson joined MJFF and led the absorption of PAN by the Foundation. Today, the Foundation is the nexus of Parkinson’s advocacy on Capitol Hill and across the country, focused on securing increased investments in Parkinson’s research, building resources for secure and effective data collection in scientific research, defending research freedom to explore all possible paths to new treatments, and ensuring that people with Parkinson’s are able to access high quality, affordable care and services. Results of these efforts to date include the creation of a federal data collection effort and several state Parkinson’s registries; increased resources at the National Institutes of Health focused on PD; and ongoing work to prioritize research into environmental triggers of PD. The Foundation also works to organize and support a nationwide community of Parkinson’s patient advocates on the front lines of educating elected officials and policy makers about the needs of people and families living with Parkinson’s.

 

According to CFCR Executive Director Sarah A. Chase, Thompson’s addition to the Board represents an important win for both organizations’ missions.

 

“We look forward to working with Ted on strategies to encourage the federal government to pass legislation and implement regulations expanding the ability of independent entities to conduct meaningful, necessary research that will benefit people and families with Parkinson’s,” she said.  “His background positions him well to help lay the groundwork for such activity.”

 

Earlier in his career, Thompson was vice president of federal government relations at the National Multiple Sclerosis (MS) Society. In this role he led significant research into cannabis and coordinated strategic lobbying efforts to eliminate its research barriers. Eight years later, several U.S. states have legalized cannabis, but the federal piece is still missing. Thompson has also independently consulted for several nonprofits, for-profit companies and political entities.

 

“Having learned about Ted’s background, and now that we are getting to know him personally, we could not have asked for a better person to be a part of CFCR,” said Board Chair Sheri Orlowitz. “Through The Michael J. Fox Foundation, Ted represents a strong, well-respected institution, whose vision and objectives are fully aligned with our own. The Board welcomes his guidance on our mission to create accessible and safe and therapeutic pathways for cannabis.”

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Council for Federal Cannabis Regulation Announces January 2022 Webinar to Discuss Cannabis, Equity, and Access to Capital

Registration Now Open for Free Virtual Event on Thursday, Jan. 20, 1pm EST

JANUARY 6, 2022

WASHINGTON, D.C. (Thursday, January 6, 2022)  – The Council for Federal Cannabis Regulation (CFCR) announced today that its next virtual webinar, “You Can’t Have Cannabis Without Equity, and You Can’t Have Equity Without Access to Capital,” will take place on Thursday, January 20, from 1:00 to 2:00 p.m. EST. Speakers will be: Wanda L. James, founder and CEO of Simply Pure Dispensary, Candace Gingrich, LGBTQ community advocate, and Bruce Linton, founder and former Chairman and CEO of Canopy Growth Corporation (CGC/WEED).

Registration is now open for the complimentary event that is part of the CFCR’s regular webinar series offering sessions that feature informative and relevant topics covered by industry experts. Visit https://www.uscfcr.org/events to register for January’s event and to view past sessions.

Speaker profiles for January 20, 2022, webinar:

 

Wanda L. James

Founder and CEO of Simply Pure Dispensary


Wanda James and her husband, Scott Durrah, became the first legally licensed African Americans to own a dispensary, a cultivation facility, and an edible company. James is a leading advocate in the cannabis industry focused on social equity and justice and has worked with many politicians on cannabis reform including former President Barrack Obama and Vice President Kamala Harris. The first inductee into the MJ Biz Cannabis Hall of Fame, James was named one of the 50 Most Important Women in the Cannabis Industry by Cannabis Business Executive (2016) and one of the 100 Most Influential People in Cannabis by High Times Magazine (2018).

Candace Gingrich

LGBTQ Community Advocate


Since 1995, Candace Gingrich has served as a key advocate for issues of importance to the LGBTQ community. Gingrich’s involvement in the movement for queer equality began when her older brother, Newt Gingrich, was elected House speaker. From 1998 to 2019, Gingrich worked for the Human Rights Campaign, crisscrossing the country to promote the importance of coming out, the duty to vote, and the power of everyday conversations to change minds. Gingrich joined Revolution Global from 2019 until 2021 and helped direct it first DEI program, continuing Revolution’s commitment to equity both internally and externally. Additional accomplishments include designing and presenting LGBTQ competence training (with focus on transgender and non-binary content) for medical cannabis dispensary staff and creating social media programming to highlight LGBTQ people, women, and veterans in the cannabis industry.

Bruce Linton

A Founder and Former Chairman and CEO of Canopy Growth Corporation (CGC/WEED)


Bruce Linton brings a wealth of experience in building strong technology driven companies, developing world-class teams and positioning companies to deliver exceptional customer value and service. In his newly appointed role as an active advisor for Mind Med, Linton will serve as Executive Chairman with GAGE Cannabis Co., following completion of the acquisition of Innovations. Linton also serves as a special advisor with Better Choice Company, an animal health and wellness cannabinoid company, and is an active investor with SLANG Worldwide Inc. (CSE:SLNG), a leading global cannabis consumer packaged goods company.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Document-Journal_Wanda-James_2-1_edited.jpg
candace-gingrich_edited.jpg
Bruce-Linton-e1580755184333.jpg

Council for Federal Cannabis Regulation (CFCR) Urges Biden Administration to Free CBD from the Drug Exclusion Rule and Allow FDA to Regulate Multi-Billion Dollar US Cannabis Market

Council Encourages Government to Actively Address Urgent Risks to Public Health and Safety Toward Ultimate Goal of Establishing a Well-Regulated Pathway Forward for the Cannabis Industry

DECEMBER 14, 2021

(EMARGO COPY – Embargo ends 9am EST on Tuesday, December 14, 2021)

WASHINGTON, D.C. (December 14, 2021)  – The Council for Federal Cannabis Regulation, (CFCR), a non-profit organization dedicated to fostering common-sense federal directives and regulations applicable to cannabis, has called upon the Secretary of Health and Human Services (HHS) to address an escalating public health and safety crisis in the US affecting children, vulnerable populations, and the general population.

 

In a letter (READ HERE) delivered on Sunday, December 12th, to the Hon. Xavier Becerra, Secretary of HHS, CFCR Board Chair, and former Department of Justice lawyer Sheri L. Orlowitz stated, “It is critical that this Administration work to overcome the Drug Exclusion Rule (DER) which the Food and Drug Administration (FDA) continuously points to as the regulatory barrier preventing it from regulating CBD and products containing CBD. The DER prohibits a molecule used in a drug to be sold as a food or dietary supplement unless the molecule was marketed as same before the FDA approved it as a new drug or began the IND investigation. The CBD molecule is the active ingredient contained in Epidiolex, a drug used to treat seizures. This is the required and critical first step to creating a national marketplace.

 

The letter emphasized that: 

 

  • This regulatory barrier has permitted psychoactive substances, including Delta-8 THC, Delta-9 THC (hemp-derived), to be introduced into food, drink, tincture, and other products, and sold with no restrictions.  

 

  • These products range from gummy worms that are virtually indistinguishable from other children’s candy to “soft” drinks, both containing psychoactive ingredients that produce intoxication. These can be found in convenience stores, gas stations, and many other storefronts, making these products easily available to children and other vulnerable populations. 

 

CFCR, whose Board, committee chairs and advisors, are a who’s who of leading industry experts, both domestic and international, as well as former federal agency leaders, has requested a meeting with HHS to amplify the concerns expressed in the December 12th  letter and to share its strategies to support federal agencies and make this a ‘win-win’ for the Administration, the legal cannabis sector, and above all, the American public. CFCR also proposes to provide FDA access to ongoing confidential toxicology studies being conducted by a well-respected research organization to support safety requirements for CBD products in the European Union and the United Kingdom. CFCR believes this information can accelerate FDA’s ability and timeline to regulate CBD, but not without first obtaining an Administration waiver of the DER to allow the FDA to proceed.

 

“Even though cannabis products are fully legal in some states and are regulated by those jurisdictions, there are still thousands of products shipped interstate every day that urgently requires oversight,” said Orlowitz. 

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.   

Council for Federal Cannabis Regulation (CFCR)december webinar to focus on pros and cons of federal cannabis regulation

next cfcr event scheduled for thursday, december 16, 1:00pm - 2:00pm est

DECEMBER 7, 2021

WASHINGTON, D.C. (December 7, 2021)  – Today, the Council for Federal Cannabis Regulation (CFCR) announced the third installment of their monthly web series. December’s virtual conversation will discuss the topic of “Pros and Cons: What We’ve Learned from the Regulation of the US Hemp Industry.” Joining the discussion will be Executive Director of the National Hemp Association (NHA) Erica Stark, along with Herrick “Rick” Fox, CEO and Co-Founder of Meristem Farms and former senior policy staff with the USDA.

 

Additionally, the webinar will feature Bill Richmond, Chief, U.S. Domestic Hemp Production Program, Specialty Crops Program, AMS, USDA, and a regulatory expert from the FDA, who will be confirmed later this week.

 

Hosts include CFCR’s own Executive Director Sarah A. Chase and Thompson Coburn LLP Advisor Jack Jacobson. The event is scheduled for Thursday, December 16th, from 1:00 until 2:00 p.m. EST.

 

With roughly 125 monthly participants already since debuting September 18th, CFCR has explored various facets of the cannabis industry in their monthly webinar series – including the regulatory impacts of a groundbreaking CBD study, as well as Federal and state cannabis policies. Ongoing webinars will take place on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today’s legal cannabis molecules and products. These virtual sessions can be viewed on WebEx. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

 

Speaker Profiles for the December 16 Webinar:

 

Erica Stark

 

Erica Stark is the Executive Director of the National Hemp Association. She is also the Executive Director of the Pennsylvania Hemp Industry Council and serves on the leadership team of the PA Hemp Steering Committee, which is an advisory council to the PA Dept. of Agriculture. Erica was instrumental in enacting legislation in Pennsylvania and has been managing permits and growing hemp in PA since 2017. She is a sought-after speaker with years of experience in hemp education and legislative advocacy, including testifying before Congress. The industrial hemp industry has experienced a rebirth, legally, and now it is time to fuel the fires and continue to breathe new life into the fledgling industry, both locally and nationally.

Herrick "Rick" Fox

 

Rick Fox is CEO of Meristem Farms, a Vermont-based producer of distinctive hemp crops and consumer products that builds capacity throughout the hemp value chain through policy leadership and public-private partnerships. Rick also co-chairs the Government Affairs Committee of the National Industrial Hemp Council (NIHC), applying his prior USDA policy and rule-making experience to support building a hemp economy that works for everyone.

 

Rick’s 25 years of professional experience spans various subjects including forestry, conservation, land management, public policy, food security and agricultural trade. Prior to starting Meristem Farms, Rick finished his 15-year USDA career as an executive in USDA’s Foreign Agricultural Service, leading a division in agricultural trade capacity-building.Before that Rick worked with USDA Forest Service, first in land management on National Forests and later in policy with senior USDA officials and the US Senate Committee on Agriculture. He also served as policy expert for USAID programs in Russia and the Republic of Georgia. In his early career, Rick lived in Russia for 6 years working on conservation and sustainable forestry in Siberia and the Russian Far East.

 

Rick holds a B.S. from U.C. Berkeley and a Master’s in Forest Science from Yale. An avid skier and hiker since early childhood, Rick recently left Washington D.C. to further hone his gravity management skills in the northern Vermont highlands with his wife and their 3 kids, except when they’re all busy chucking hemp.

Bill Richmond

 

Bill Richmond, Chief, USDA Hemp Program, leads the team responsible for the establishment and implementation of the U.S. Domestic Hemp Production Program.  The USDA hemp program oversees State and Tribal hemp regulations, producer licensing, laboratory compliance testing, rulemaking, intergovernmental affairs and stakeholder outreach.  He has been in Federal service, all with USDA, for 22 years.  In other roles, he led the Country of Origin and Bioengineered Food Labeling Programs and served as the chief of staff of the Agricultural Marketing Service under the Obama and Trump administrations.  He studied agricultural economics at the University of Maryland and holds professional certificates from the Harvard Kennedy School of Government and the Brookings Institution.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.   

Erica (1)_edited.jpg
Rick31_LowRes_edited.jpg
Bill-Richmond.jpg

Jim Esquea, VP, Public Affairs, for

The Scotts Miracle-Gro Company Named to Board of Directors Of the Council for Federal Cannabis Regulation (CFCR)

DECEMBER 1, 2021

WASHINGTON, D.C. (December 1, 2021)  – The Scotts Miracle-Gro Company and the Council for Federal Cannabis Regulation (CFCR) jointly announced today that the company’s Vice President of Public Affairs, Jim Esquea, will join the CFCR leadership as a member of their Board of Directors.

 

Esquea brings to this role more than 25 years of policy experience, having previously served as Assistant Secretary for Legislation at the U.S. Department of Health and Human Services in the Obama Administration, as a senior analyst for the U.S. Senate Budget Committee and budget analyst in the Office of Management and Budget in the Clinton Administration. 

 

“On behalf of ScottsMiracle-Gro I’m excited to join CFCR’s leadership team and their mission to assist the government, and its federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations,” said Esquea. “ScottsMiracle-Gro, through its subsidiary The Hawthorne Gardening Company, is a leading provider of nutrients, lighting and other materials used in indoor and hydroponic growing and have unique insights about the emerging cannabis industry. With 37 states having approved cannabis for recreational or medical use, the federal policy dialogue around cannabis will only intensify … and we look forward to contributing to the conversation and working with CFCR.”

 

For CFCR, the connection with Esquea and ScottsMiracle-Gro has natural synergy.

 

“We enthusiastically welcome ScottsMiracle-Gro and Jim Esquea to our ranks,” said Council Founder and Board Chair Sheri Orlowitz.  “Jim is both brilliant and kind; very much CFCR values.   Our mission – to destigmatize, legitimize and normalize cannabis through working as an objective third party with the federal agencies – aligns perfectly with Scotts’ perspective and Jim’s storied career that spans over two decades with the federal government.  Having served as an HHS Assistant Secretary for Legislation, Jim will bring critical insight to our work with federal agencies, a key asset to helping both the FDA and HHS understand and embrace the cannabis industry.

 

 

Named to his position in April of 2021, Esquea is the company’s first position based in Washington, DC. He leads the company’s day-to-day federal outreach on issues that range from cannabis and social justice reform to environmental regulation, consumer protection and corporate tax policies.  He most recently served as the Senior Director of Federal Affairs for Juul Labs Inc. A graduate of Wesleyan University, Esquea also holds an M.P.A. from Columbia University.

 

About CFCR

 

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink, develop, and implement evidence-based cannabis regulations. Our overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. We do this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

 

 

About ScottsMiracle-Gro

 

With approximately $4.9 billion in sales, the Company is one of the world’s largest marketers of branded consumer products for lawn and garden care. The Company’s brands are among the most recognized in the industry. The Company’s Scotts®, Miracle-Gro® and Ortho® brands are market-leading in their categories. The Company’s wholly owned subsidiary, The Hawthorne Gardening Company, is a leading provider of nutrients, lighting and other materials used in the indoor and hydroponic growing segment. For additional information, visit www.scottsmiraclegro.com.

####

Council for Federal Cannabis Regulation (CFCR) to Offer International Cannabis Regulation Insight in Upcoming November 19 Webinar

NOVEMBER 11, 2021

WASHINGTON, D.C. (November 11, 2021)  – Following the successful launch of its monthly webinar series in September 2021, the Council for Federal Cannabis Regulation (CFCR) today announced “International Cannabis Regulation: Informing a Pathway for the US Agencies” as the topic for November’s virtual conversation. Joining the discussion will be seasoned policy advisor and current Managing Director of the European Industrial Hemp Association (EIHA) Lorenza Romanese, along with Dr. Palmer Orlandi, Deputy Executive Director and Chief Science Officer at AOAC International (formerly known as the Association of Official Analytical Chemists) and Oscar Hackett, CFO and President of Open Book Extracts.  Hosts include CFCR’s own Executive Director Sarah A. Chase and Thompson Coburn LLP Advisor Jack Jacobson. The event is scheduled for Friday, November 19, from 1:00 until 2:00 p.m. EST.

 

With roughly 125 monthly listeners already since debuting September 18th, CFCR has explored various facets of the cannabis industry in their monthly webinar series – including the regulatory impacts of a groundbreaking CBD study, as well as Federal and state cannabis policies. The Council has committed to organizing a webinar on the second or third Thursday of every month (depending on holidays), each to spotlight a wide range of industry professionals and focus on preparing to regulate and regulating today’s legal cannabis molecules and products. The virtual sessions can be viewed on WebEx and will feature a moderator accompanied by two-to-three panelists. Each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A for a total run-time of approximately one hour.

 

Speaker Profiles for the November 19 Webinar:

 

Lorenza Romanese

 

A brilliant strategist and fierce advocate for policy and reform, Lorenza Romanese is the present Managing Director of the European Industrial Hemp Association (EIHA) and has led its efforts in Brussels since early 2019. Romanese has a proven background in communications at the European-level and in suggesting reforms related to hemp in the EU’s Common Agriculture Policy. She previously led the European Association of Independent Winegrowers and specialized in interests in both the gas and oil sectors

Oscar Hackett

 

President and CFO of Open Book Extracts and a graduate of Georgetown and Harvard University Law School, A member of the CFCR Executive Committee, Oscar Hackett is a new venture formation and capitalization expert with multiple start-ups built and exited. Oscar is a strategic CFO and GC with deep fundraising (equity and debt) and regulatory experience.

Palmer A. Orlandi, Jr.

 

Deputy Executive Director and Chief Science Officer at AOAC INTERNATIONAL, Palmer Orlandi, Jr. oversees the AOAC Research Institute, Standards Development Activities, and the Proficiency Testing Program. He also manages business development which includes strategic partnerships with the goal of advancing voluntary consensus standards-setting activities and strengthening international relations.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) non-profit based in Washington, DC. The mission of CFCR is to assist the government, and specifically federal regulatory agencies, to rethink cannabis regulations. CFCR’s overarching goal is the de-stigmatization, normalization, and legitimization of cannabis on behalf of consumers, the professions, organizations, and businesses who support and serve them. CFCR does this by serving as a conduit for informed scientific research, inclusive education, and by mainstreaming the best practices that enable the industry to maximize its potential. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.   

Lorenza HS_edited.jpg
1516305607452.jpeg
Palmer-270x300_edited.jpg

Webinar to Examine Critical Federal and State Cannabis Regulation

Next Council for Federal Cannabis Regulation Event Scheduled for

Thursday, October 28, 1:00 EST

OCTOBER 18, 2021

WASHINGTON, D.C. (October 18, 2021)  – The Council for Federal Cannabis Regulation (CFCR) today announced the next webinar in a series of monthly informative sessions titled “Cannabis Regulation: What the Federal Government Can Learn from the States.” It is set to take place on Thursday, October 28, beginning at 1 p.m. EST. The webinar will call upon two experts in the cannabis industry – Dr. Gillian Schauer, Executive Director of Cannabis Regulators Association (CANNRA) and Toi Hutchinson, Senior Advisor to Governor JB Pritzker for Cannabis Control. The discussion will be hosted by Sarah A. Chase, CFCR’s Executive Director, along with Jack Jacobson, Advisor at Thompson Coburn LLP.

 

CFCR launched its virtual webinar series last month with a discussion tackling the regulatory impacts of a groundbreaking CBD study. The Council will continue to host an educational webinar on the second or third Thursday of every month, depending on holidays. The sessions can be viewed over WebEx and will each feature a moderator accompanied by two-to-three panelists. Scheduled to run for approximately one hour, each webinar will consist of a 40-minute interactive conversation followed by approximately 20-minutes of moderated audience Q&A.

 

Speaker Profiles for the October 28 Webinar:

 

Gillian Schauer: Prior to CANNRA’s founding, Gillian Schauer, PhD, MPH served as a Senior Advisor before she was elected the organization’s first Executive Director in 2021. She brings nearly 20 years of experience in public health and policy to the role of Executive Director and has an extensive background in partnering with federal and state agencies on cannabis policy, data monitoring, and research translation. Dr. Schauer also founded the Multi-State Collaborative for Cannabis and Public Health and led its initiatives from 2014 to 2021

 

Toi Hutchinson: A former member of the Illinois State Senate, Toi Hutchinson represented the 40th District from 2009 to 2019 and advocated for causes that include protecting women and children from violence and legalizing cannabis. Hutchinson is an original co-sponsor of the Cannabis Regulation and Tax Act (CRTA), which aims to legalize adult-use cannabis in an equity-centric manner. She was appointed in 2019 to serve as the Senior Advisor to the Governor for Cannabis Control by Illinois Governor J.B. Pritzker.

To register for this CFCR’s webinar series, please visit: https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

gillian_schauer_001_lowres_crop_2.jpeg
ToiHutchnson_Picture1.jpg

Council for Federal Cannabis Regulation (CFCR) discusses groundbreaking new cannabis study in cfcr's webinar debut

OCTOBER 1, 2021

WASHINGTON, D.C. – The Council for Federal Cannabis Regulation (CFCR) last Thursday launched its inaugural monthly webinar series in which regulators and industry professionals will participate in moderated conversations regarding responsible cannabis regulation. Last week’s webinar focused on the impact of a groundbreaking CBD study published in the top international peer-reviewed medical journal, JAMA, and, which demonstrated a positive therapeutic effect of CBD with a defined dose in a randomized clinical trial on reduction of anxiety, depression, fatigue in front line health care workers.

 

The webinar featured guest speaker Dr. Vicki Seyfert-Margolis, a former FDA leader and Chairwoman of the Science & Regulatory Affairs Committee for CFCR, along with moderators Jack Jacobson from Thompson Coburn LLP and CFCR’s own Executive Director Sarah Chase.

 

The webinar focused on how the study was conducted, that is, in a hospital, using front line healthcare workers, which made gathering data much easier and more cost effective. The study demonstrated that medically valid “randomized controlled” trials (RCT) can be done with cannabinoids, including clinical assessments for safety and efficacy using such well-known and understood tools as blood tests, and standard medical grade scales for assessments. This study can be a “blueprint” for other cannabinoid researchers to model and provide the science the FDA is seeking.

 

One big takeaway is while close to 5% of the study participants experienced mild to serious elevated liver enzymes, the liver enzymes returned to normal after discontinuation of CBD.

 

The monthly webinar series will continue over WebEx on Thursday, October 28 with a focus on what federal regulators can learn from current state laws, regulations, and the best practices governing cannabis. This webinar will feature panelists from various state legislative offices and current cannabis regulators.

 

View a recording of the Webcast at https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

 

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Council for Federal Cannabis Regulation (CFCR) Engages Four Diverse Communication Partners to Enhance Brand Awareness Through Strategic Messaging

SEPTEMBER 28, 2021

WASHINGTON, D.C. – The Council for Federal Cannabis Regulation (CFCR) today announced formal partnerships with four communication agencies to develop concise and impactful messaging across several fronts -- including public relations, social media and graphics, creative video and visual content, and web design. Through powerful crafting and delivery of their messaging, CFCR’s intends to maximize its outreach as an advocate for federal regulations in the cannabis industry.

 

Brotman | Winter | Fried (BWF), part of the Sage Communications umbrella, will provide CFCR with public relations and outreach support. Steve Winter, President and COO of BWF, will serve as the driving force behind the development of CFCR’s messaging and the delivery of the council’s various programs and initiates to the public. Winter will also serve as the key messaging strategist on the CFCR Advisory Board. BWF is a PR agency that is well connected with various industries, including sports, entertainment, technology, and cannabis.

 

Heather Mahoney, President of the Haute Haus agency, will lead the Council’s digital campaign as Social Media Director through online marketing, social posting and marketing, and graphic design. Mahoney’s creative approach combined with her ability to generate and maintain brand awareness across various social media platforms positions her as a key player in CFCR’s communications strategy.

 

CFCR will also collaborate with Wild Bill, a content creation company based in Los Angeles. Wild Bill’s Creative Director Samantha Hart said she’s thrilled to have the opportunity to partner with CFCR. “As award-winning storytellers, nothing excites us more than crafting messaging that delivers results. We look forward to creating strategic materials for CFCR, and to collaborating with the team," Hart said.

 

Lead creative and graphic design communicator, Derek Friday, founder of Friday Farms Creative, built the CFCR brand voice and style while implementing a refreshed website and will assist in supplying that continuity across all channels.

 

“With BWF, Haute Haus, Wild Bill and Friday Farm, CFCR will benefit from the combined and collaborative efforts of four incredibly creative and diverse firms, all of whom are already collaborating in strategic rhythm to deliver our Council’s messaging across multiple platforms and formats,” said CFCR Executive Director Sarah Chase. “Each of these companies brings a unique yet complementary realm of expertise to our organization, and we’re seeing amazing results from this alliance. CFCR’s education, advocacy, and communication mission is being realized.” For additional information, please visit uscfcr.org.

 

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

ABOUT BWF

Brotman|Winter|Fried is a subsidiary of Sage Communications, headquartered in suburban Washington, D.C. A boutique firm in business for more than 40 years, BWF specializes in public relations, special event production and management, brand development, marketing and promotions for a broad range of clients including sports, entertainment, retail, restaurants, healthcare, cannabis, business services, trade associations, even local and federal government agencies. For additional information, please visit https://bwf.aboutsage.com. For a specific look at the company’s cannabis practice, please visit https://bwfcannabispr.com.

 

ABOUT HAUTE HAUS

Haute Haus is a strategic communications agency based in Chevy Chase, MD specializing in brand building through advertising, digital development, and publicity. HHA’s creative team believes PR lies in impactful content creation, including well-rounded social campaigns, engagement, and a strong brand narrative. Every team member hired has an extensive background in press, giving HHA a unique perspective in a diverse industry. For more information, please visit www.hautehausagency.com.

 

ABOUT WILD BILL

Wild Bill is an award-winning creative content and commercial agency specializing in authentic stories for entertainment properties, nonprofits, brands, and start-ups founded by Samantha Hart and James Lipetzky. Together, they have created content for American Express, Microsoft, Sony, and nonprofits A Better LA, A Place Called Home, Boys and Girls Club, and United Way, winning them the prestigious Gold Hugo Award. License to Operate, their feature documentary about reformed gang members in Los Angeles, debuted at SIFF and won Best Documentary Feature at the Highland International Film Festival

 

ABOUT FRIDAY FARMS

Friday Farms is a boutique, independent advertising, and creative design firm based in Washington, DC. Building brands and marketing strategies across multiple industries, including non-profits, start-ups, hospitality groups, and real estate sales firms, Friday Farms is committed to a collaborative environment to best communicate, represent, and target the desired audience no matter the industry or field.

Council for Federal Cannabis Regulation (CFCR)Launches Monthly Webinar Series to Begin
This Thursday, September 23

SEPTEMBER 17, 2021

WASHINGTON, D.C. – The Council for Federal Cannabis Regulation (CFCR) today announced the launch of a new monthly webinar series in which regulators and industry professionals will participate in moderated conversations regarding responsible cannabis regulation. CFCR’s Executive Director, Sarah A. Chase, says these webinars will explore industry best practices, while service to further the Council’s position as an industry leader for educating and advocating for forward-thinking and inclusive federal laws for the cannabis industry.

The series begins this Thursday, September 23, as CFCR launches its lineup with a virtual conversation titled Council for Federal Cannabis Regulation: Understanding the Regulatory Impact of a Groundbreaking New CBD Study. The webinar will feature Vicki Seyfert-Margolis, Chairwoman for Science & Regulatory Affairs Committee for CFCR, along with moderators Jack Jacobson from Thompson Coburn LLP and CFCR’s own Executive Director Sarah Chase.

The webinars will take place over WebEx on the second or third Thursday of every month, depending on holidays. The next event is scheduled for Thursday, October 28 and will focus on what federal regulators can learn from the states where cannabis is now legal. Each session will feature a moderator, and panelists or a fireside chat. Scheduled to begin at 1:00 p.m., EDT to run for approximately one hour, each webinar will consist of a 40-minute interactive conversation session followed by approximately 20 minutes of moderated audience Q&A.

Link to sign up and register for CFCR’s webinar series: https://www.uscfcr.org/events

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Council for Federal Cannabis Regulation Publishes Solutions-Driven Response to the Proposed Legalization Act

SEPTEMBER 8, 2021

CFCR’s Science and Regulatory Affairs Committee Provides Solutions for a Clear Pathway Forward for Federal Legalization with Published Comments to The Cannabis Administration and Opportunity Act (CAOA)

WASHINGTON, D.C. – The Council for Federal Cannabis Regulation (CFCR) today announced several key positioning statements in response to the Cannabis Administration and Opportunity Act (CAOA), recently supported and sponsored by the offices of Senators Booker, Schumer and Wyden.

Uniquely positioned as a solutions provider for both the federal government and the cannabis industry, CFCR is a non-profit organization developed to have broad and deep expertise, CFCR is informed by multifaceted perspectives, enabling it both to educate the federal agencies and the public.

 

Some of the key takeaways from CFCR’s comments include:

 

  • CFCR applauds the CAOA drafters for putting forward this discussion draft and for the transparent approach they have taken to the process. We support the fundamental approach and process. 

 

  • CFCR suggested strategies to curb bad actors, provide for interim regulations, a consortium to do safety testing (if needed), and other suggestions of how we may help to expedite the regulatory process.

 

  • CFCR’s proposed definition of cannabis does not exclude hemp, for the simple reason that cannabis and hemp are the same plant. CFCR notes that the ≤0.3% THC threshold is an arbitrary limitation that inhibits various industries and research inquiries.

 

  • CFCR suggested >1% as a threshold for High-THC cannabis. CFCR notes that as research develops other thresholds might be established, but >1% THC as the threshold for High-THC Cannabis and ≤1% THC for Low-THC Cannabis should find support at this time  

 

  • A Center for Cannabis Products as a separate entity, wherever housed, should establish a unique product standard for cannabis products. 

 

  • Cannabis products should be a separate product category for purposes of regulation and should not be shoehorned into the existing product categories, (e.g., foods and dietary supplements). 

 

  • CFCR does not support the use of GRAS and NDI for Cannabis products because Cannabis products are unique due to already being on the market and regulated at the state level. Retroactively applying NDI and GRAS to these products is not practical. More importantly the safety profile of these products is significantly different. A new Cannabis product safety standard must be developed.

 

  • In support, CFCR also suggests that the CAOA include an immediate authorization of appropriations that is sufficient to allow the FDA to staff appropriately in order to develop new and more expeditious ways to review Cannabis constituents, as well as full-spectrum or broad-spectrum products.

 

CFCR is a 40-person organization including an eight-person Science and Regulatory Affairs Committee (SRA) comprised of three PhD scientists, a world-renowned big data expert, FDA lawyers and researchers, as well as a variety of other professionals.

 

“CFCR was developed with topflight experts who can bring tools and strategies, as well as advocacy, to the federal agencies to help develop the cannabis industry safely and with all due haste,” said CFCRs Board Chair Sheri Orlowitz.

 

With its recently submitted comments (READ HERE) to the Sponsoring Offices of the Senators regarding the draft discussion of CAOA, CFCR has established itself as a unified voice for diverse industry and a trusted source of accurate science and policy guidance.

 

“Our primary focus is to work with the FDA on the regulation of cannabinoids,” said CFCR’s new Executive Director, Sarah Chase.  “CFCR’s comments to the CAOA are the product of this singular focus and we are bringing a novel solutions-driven approaches to the complex effort to federally regulate a plant that has been illegal for eight decades, with safety, fairness and efficiency.”

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Council for Federal Cannabis Regulation Introduces New Executive Director

AUGUST 30, 2021

Sarah Chase Brings 20 Years of C-Level Experience With Startups, Media Properties and Corporations to Council’s Mission to Support Federal Laws and Regulations to Govern the Cannabis Industry

WASHINGTON, D.C. -- Sheri Orlowitz, Founder and President of the Council for Federal Cannabis Regulation (CFCR), announced today the appointment of Sarah A. Chase as the organization’s first Executive Director.  A lifelong creator and business professional who has worked diligently behind the scenes at various organizations to champion both public and private projects that are mission-driven and deliver social impact, Chase brings direction, focus and motivation to the Council’s mission to educate, advocate, communicate and support the creation of informed, intelligible, and inclusive federal laws and regulations for the cannabis industry.

 

“My vision for CFCR is to ensure that we become – and will always remain -- the most trusted, and collaborative resource for the federal regulatory agencies, Congress, the White House, and the diversity of stakeholders within the cannabis industry,” Chase said. “Through our committee structure, our leadership, and our partner organizations, CFCR has been carefully structured to be the most dependable conduit through which information, knowledge, and accurate scientific information and research can be shared to ensure a safe and legal regulatory pathway. CFCR is here to help educate, to advocate, and communicate. And it is my firm belief and vision that we must always to do so with honesty, efficiency, and integrity.”

 

For nearly two decades, Chase has worked primarily with start-up companies in the media, broadcast and communication space. She has held various COO, CFO, Communication, and Business Development positions and has worked closely with executive teams in the United States, Europe and Asia to translate high-level visions into realized corporate entities.

 

From 2016 through 2020, Chase served as the Chief Operating Officer for Alan Alda’s Communication Training Company (ACT), mentoring with the legendary actor, writer and director while helping to bring his proven improv and communication methods to the world. Working closely with Alda, Chase established the first-of-its-kind public-private partnership (PPP) with the State University of New York (SUNY). The company grew from ground zero to more than $2.5M in net profit within the first two years. Because of this growth and success, Alda achieved his dream of donating the profits directly back to the Alan Alda Center for Communicating Science at Stony Brook University, to further advance the better communication of science

 

As the Executive Producer, writer, and voice-over artist for Alda’s Clear+Vivid, podcasts, Chase produced in excess of a hundred episodes generating more than 15 million downloads. The lineup included such notable guests as Tom Hanks, Paul McCartney, Julie Andrews, Madeline Albright, Tina Fey, Michael J. Fox, Judge Judy, Isabella Rossellini and others.

Chase previously led communication and media training workshops for several corporate clients as well as at the United Nations, NASA, the Nature Conservancy and various "Shark Tank" events. She has served as an executive committee member of the National Small Business Association in Washington, D.C. and was as a featured panelist and consultant with the Global Coalition for Aging at the Council on Foreign Relations.  Earlier in her career she worked in both London and Frankfurt, advising a diverse range of clients and companies. She also served as a featured political commentator on Sky News and BBC Radio. 

 

“Sarah’s expertise in the fields of communication, fundraising and business development uniquely qualifies her for this role,” said Orlowitz.  “Her passion for justice and social causes meshes perfectly with the Council’s overall mission.”

 

For additional information, please visit uscfcr.org.

####

 

ABOUT CFCR

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.  

Council for Federal Cannabis Regulation (CFCR) Congratulates its Science Co-Chair, Co-founder and Executive Chair of Radicle Science on Most Comprehensive US Trials Measuring Impact of CBD

AUGUST 24, 2021

Largest and Most Comprehensive Randomized Controlled Trial of Its Kind Helps Fill
Gap Created by Limited Real-World Evidence on Public Understanding and Use

WASHINGTON, D.C. -- According to a recent survey by data research and control management company Invisibly, nearly 60 percent of all Americans have no viable understanding of CBD. By and large, they don’t know what it stands for, what it means, nor what it does. A colloquial contraction for cannabidiol, CBD is a chemical compound found in the same plant that produces cannabis (marijuana) and hemp. Naturally occurring and fully-holistic, CBD is now widely used in oils, topicals, and ingestibles for wellness purposes and other physical and mental need states.

Through a survey of more than a thousand Americans designed to shed light on our population’s understanding of these products, 62 percent have never used any iteration of the product, and among that group, 68 percent indicated they were ignorant as to the difference between CBD and THC-infused products such as medical and recreational cannabis. Actually, that’s not surprising ... after all, there has been relatively little in the way of peer- reviewed documentation about this increasingly popular health-related supplement ... but thanks to a real-world evidence study recently launched by Radicle Science, a San Diego-based,
transformative healthtech B-corp, that’s about to change.


Earlier this month Radicle Science announced the launch of its Radicle ACES (Advancing CBD Education and Science) Study, the largest and most comprehensive randomized controlled trial of its kind, designed to capture CBD effectiveness data directly from nearly 3,000 study participants. The study has received Institutional Review Board (IRB) approval, which is generally recognized as a standard for the FDA in assuring the safety and well-being of human participants. IRB approvals are currently rare among the industry, and this further demonstrates the high-standards of this scientific study.


During the four-week trial period, scheduled to conclude in late September, participants will track consumption and effectiveness of orally-ingested CBD products from 13 major U.S. CBD brands, focusing on well-being, quality of life, and other common physical and mental need states. Radicle ACES will use validated, standardized health indices to gather health outcome data from a diverse population across a variety of ethnicities, age groups, geographies, behavioral habits, and pre-existing health conditions. The real-world evidence collected will inform scientific understanding on usage patterns, user characteristics, effectiveness across conditions, and predictors and modifiers of response. And quite frankly, the leadership at the Council for Federal Cannabis Regulations (CFCR)
could not be happier.

“This study represents sound, accurate, and responsible scientific research, which continues to create intelligible and inclusive pathways for CBD products,” said Council Founder Sheri L. Orlowitz, whose organization’s primary goal is to interface with the FDA on how to proceed with cannabis safety testing, research, and regulation on behalf of currently existing and future cannabis producers. “Studies of this magnitude are needed in order to put public health and safety first and foremost, as the entire cannabis industry is faced with federal regulation and the need for data, science and expertise. CFCR recognizes that further understanding and dialogue is needed to better align cannabis industry policy, scientific research and data, and regulatory measures. Our mission is to help bridge that gap not only through advocacy, education, and clear-cut communication but also by sharing knowledge and expertise from our international partners around the world and our eight-person science team with four PhDs." 

According to Radicle’s founding team, this study will achieve precisely that. “A rigorous scientific study of this magnitude has never before been conducted in the CBD market,” said Pelin Thorogood, Co-founder and Executive Chair of Radicle Science. “Radicle ACES is driven by our deep commitment to contribute to the body of evidence to support growing demand from consumers and healthcare providers.


“Given the scale, the diversity of the participant population and the wide range of high-quality commercial brands included, Radicle ACES promises to deliver rich, objective health outcome data for a variety of common health-related complaints, with the potential to offer unprecedented guidance on CBD effectiveness based on demographic or behavioral differences.” As Co-Chair of the Science and Regulatory Affairs Committee (SRA) for CFCR, Thorogood brings this perspective and expertise to the CFCR team.


The brands being tested in the study are fully supportive of this research. According to a quote from Dr. Kenton Crowley, Director of Research and Development who is overseeing the production of Trokie, one of the 13 brands integrated into the study, “the collaboration between Radicle Science, academic medicine and therapeutically-focused cannabinoid brands makes this trial particularly exciting. We are thrilled to be a part of a rigorous investigation into how Trokie and other clinically relevant CBD products can improve the lives of consumers and also hopefully expand the avenues for more clinical cannabinoid research.” The other brands included in the trial include ALTWELL, Charlotte’s Web, Columbia Care, Healer, Lord Jones, Maven Hemp, MD FARMA, Peels, Prospect Farms, PURAURA Naturals from Enhanced Botanicals, Rae Wellness and Verséa Wellness.

 

For additional information, please visit uscfcr.org.

 

####

 

ABOUT CFCR
The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.

 

ABOUT RADICLE SCIENCE
Radicle Science is a transformative healthtech B-corp offering the first-ever path to natural product validation at scale. Radicle Science disrupts the traditional clinical trial model by combining the reach of a market research company, the scientific rigor of a research university, and the agility of a tech company. Operating at the intersection of big data, digital health and natural products, Radicle Science leverages a proprietary data analytics platform and a virtual, direct-to-consumer (D2C) model to deliver objective health outcome data across diverse populations and conditions. Our Radicle Vision is a future where affordable, accessible, natural health products are trusted by patients, recommended by healthcare providers, reimbursed by insurance, and used as widely as pharmaceutical drugs. To learn more, please visit www.radiclescience.com and follow their LinkedIn page.

Council for Federal Cannabis Regulation (CFCR)Ramps Up Mission Activity through Series of Events

And Engagement of New Key Personnel

AUGUST 18, 2021

WASHINGTON, D.C. -- The Council for Federal Cannabis Regulation (CFCR) launched last year as an umbrella organization designed to advocate for federal regulations to enhance public faith and trust in cannabis-infused products as the industry continues to approach full nationwide legalization. 

 

CFCR’s initial mission is to work with federal agencies, including the U.S. Food & Drug Administration and even the White House to develop a safe “legal” harbor for all non-THC products in the marketplace today, and to expedite the development of a legal regulatory pathway. The organization has quietly attracted top talent for this initial mission, including four PhD’s, and has largely flown under the radar awaiting a new FDA Commissioner to begin its critical work.

 

According to Council Founder Sheri L. Orlowitz, CFCR’s “quiet approach” to this point is about to change.

 

Through the appointment of a new executive director and the engagement of a powerful team of industry and federal government professionals – ranging from scientists and C-Level corporate executives to attorneys, financial experts and cannabis industry specialists – the non-profit Council is now poised to embark on its core mission objectives: namely to represent the interests of the current and future industry stakeholders as cannabis continues to face increased regulation by various federal agencies.

 

“CFCR was designed to provide tools, business guidance and scientific resources to support the FDA’s process to regulate cannabis compounds; to attract and educate established industry and encourage its support and investment in the regulatory process and to ensure regulations are informed by and grounded in the policies behind legalization such as access to cannabis without undue burden and restorative justice,” said Orlowitz, a former Department of Justice Prosecutor who is also a Founding Partner of Artemis Holdings, a Board Member of the Marijuana Policy Project and a Founding Member of the US Cannabis Council.  “These objectives will be achieved by a series of programs CFCR will facilitate, designed to inform and support FDA safety requirements, developing an agreed path for cannabis, building off accurate science, extensive research studies and best practices from other countries and educating and attracting hesitant stakeholders and encouraging them to invest in regulation.”

 

The FDA, Orlowitz says, ultimately holds the key to the eventual widespread acceptance and integration of cannabis-related product into the marketplace. 

 

“In addition to medical-use cannabis, the huge demand for CBD is not being met because producers are operating under a fog of regulatory uncertainty, and consumers do not know which are trusted products. The CFCR will work with consumer-packaged goods and cannabis company stakeholders to explore and recommend a pathway for FDA approval of cannabis-infused products as a dietary supplement and food additive.”

 

 

CFCR was created as a “think and do” tank to serve as a forum in which stakeholders – both from the federal government and industry – will analyze and support the creation of informed federal laws and regulations to safely govern the cannabis industry without being unduly burdensome. The Council is composed of four committees: a Scientific and Regulatory Affairs Committee, a Corporate and Business Committee, a Legal and Government Relations Committee and a DEI Committee, each led by best-in-class experts in their respective fields.

 

For additional information, please visit uscfcr.org.

 

####

 

ABOUT CFCR

 

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit www.uscfcr.org and follow us on social media @USCFCR.